Sex differences in inflammatory biomarkers during long-term evolocumab therapy
Our findings reveal pronounced biological sex differences in inflammatory responses to long-term evolocumab therapy, highlighting the need to incorporate sex-specific considerations in cardiovascular risk management and treatment monitoring. These novel insights pave the way for personalized therapeutic strategies and call for further investigation into the clinical significance of inflammation in lipid-lowering treatment outcomes.
Authors
- Dmitri Mitselman
- Gökmen Zararsız (ORCID: https://orcid.org/0000-0001-5801-1835)
- Marina Giovannini (ORCID: https://orcid.org/0000-0002-6563-0439)
- Serra İlayda Yerlitaş (ORCID: https://orcid.org/0000-0003-2830-3006)
- Egidio Imbalzano (ORCID: https://orcid.org/0000-0003-2656-5467)
- Claudio Borghi (ORCID: https://orcid.org/0000-0001-8039-8781)
- Arrigo F.G. Cicero (ORCID: https://orcid.org/0000-0002-4367-3884)
- Federica Fogacci (ORCID: https://orcid.org/0000-0001-7853-0042)
Institutions
- University of Messina (IT)
- Erciyes University (TR)
- University of Bologna (IT)
Publication Details
- Journal
- Journal of clinical lipidology
- Published
- 2025-11-16
- DOI
- https://doi.org/10.1016/j.jacl.2025.11.011
- Primary Topic
- Atherosclerosis and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00